Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siRNA targeting Apex1
- Development stage
- Preclinical
- Lead developer
- Universidad de Navarra
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intraarticular
01
Overview
siRNA targeting Apex1 is a small interfering RNA (siRNA) therapeutic designed to silence the expression of apurinic/apyrimidinic endodeoxyribonuclease 1 (APEX1) [181]. APEX1 is a multifunctional protein involved in DNA base excision repair and cellular response to oxidative stress, and it plays a key role in chondrocyte hypertrophy and osteoarthritis progression [181]. In preclinical models of osteoarthritis, intra-articular administration of siRNA targeting Apex1 has been shown to delay cartilage degradation, reduce proteoglycan loss, and decrease the expression of matrix metalloproteinase 13 (MMP13), suggesting its potential as a biological and pharmacological treatment for osteoarthritis [181].
- Other names
- si-APEX1si-APEX-1si-APEX 1siAPEX1siAPEX-1siAPEX 1siRNA targeting APEX1
02
Targets
APEX1 (DNA-apurinic apyrimidinic site lyase)
Beyond the preview
Go deeper on siRNA targeting Apex1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siRNA targeting Apex1.